US pharmaceutical company Gilead is blocking the purchase of a hepatitis C generic drug that would save the Brazilian government R$ 1 billion (US$ 275 million) a year.
Leia mais (09/11/2018 – 16h46)
Original published: 2018-09-11 16:46:00 Read the full Sao Paulo News here
Some local news is curated - Original might have been posted at a different date/ time! Click the source link for details.